Standardisation of terminology, calculation and reporting for assigning exposure duration to drug utilisation records from healthcare data sources: the CreateDoT framework
Riera-Arnau, J.; Paoletti, O.; Gini, R.; Thurin, N. H.; Souverein, P. C.; Abtahi, S.; Duran, C. E.; Pajouheshnia, R.; Roberto, G.
Show abstract
BackgroundIn pharmacoepidemiological studies, days of treatment (DoT) duration associated with individual electronic drug utilization records (DUR) are usually missing. Researcher-defined duration (RDD) calculation approaches, as opposed to data-driven approaches, can be used to estimate DoT based on the specific choices and assumptions made by investigators. These are usually underreported or even undocumented. We aimed to develop a framework for the standardization of terminology, formulas, implementation, and reporting of possible RDD approaches. MethodsA systematic classification of RDD calculation approaches was developed via expert consensus. Universal concepts used to operationalise RDDs were identified and described using standard terminologies. An open-source R function, CreateDoT, was created to implement the formulas universal concepts as input parameter. A step-by-step workflow was developed to facilitate implementation and reporting. ResultsRDD approaches were classified in two main classes: I) daily dose (DD)-based calculation approaches (n=3 formulas), and II) fixed-duration approaches (n=2). Seven universal concepts were identified to describe the five corresponding generalized formulas for DoT calculation. Input parameters of the CreateDoT function can be retrieved from source data through its mapping to universal concepts, or inputted by the investigator based on the chosen calculation approach. The input file structure itself represents a standard reporting template for documenting investigators assumptions and methodological choices adopted for DoT calculation. ConclusionsThe CreateDoT framework can facilitate the documentation and reporting of RDD approaches for DoT calculation, increasing transparency and reproducibility of pharmacoepidemiological studies regardless of the data model used, and facilitates sensitivity analyses to evaluate the impact of alternative assumptions in DoT calculation.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 96%
- Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies 96%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 93%
Similar papers in this journal
- A data-driven pipeline to extract potential side effects through co-prescription analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up 95%
- Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis 91%
- Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score 91%
Similar papers in this journal
- DigiLoCS: A Leap Forward in Predictive Organ-on-Chip Simulations 93%
- Applying Historical Data in a Nonlinear Mixed-Effects Model Can Reduce the Number of Control Rats Required for Calculation of the Relative Potency of Insulin Analogues 93%
- Analysis of clinical trial registry entry histories using the novel R package cthist 93%
Similar papers in this journal
- INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety 94%
- Pregnancy pharmacoepidemiology: How often are key methodological elements reported in publications? 90%
- Using quantitative bias analysis to adjust for misclassification of COVID-19 outcomes: An applied example of inhaled corticosteroids and COVID-19 outcomes 90%
Similar papers in this journal
- Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing 93%
- Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan 92%
- stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments. 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.